Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Feb 2010

Govindan Ramaswamy

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Multicenter Studies as Topic
Share to Patient Selection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Randomized Controlled Trials as Topic

Share to ras Proteins

Source

Identifiers

PMID: 20038722
DOI: 10.1200/JCO.2009.25.1637

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.PMID 20038722Read ↗

Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.Semantic proximity Read ↗

EGFR pharmacogenomics: the story continues to mutate and evolve.Semantic proximity Read ↗

EGFR testing in lung cancer is ready for prime time.Semantic proximity Read ↗

Receptor tyrosine kinase mutations: molecular indicators for therapeutic response or signposts marking important signaling pathways?Semantic proximity Read ↗

[EGFR/HER1: a target life].Semantic proximity Read ↗

Predictive tests for EGFR inhibitors.Semantic proximity Read ↗

Reasons to be testing: the dawn of complex molecular profiling in routine oncology practiceSemantic proximity Read ↗

Cancer molecular markers: A guide to cancer detection and management.Semantic proximity Read ↗

[Molecular diagnostics in oncology].Semantic proximity Read ↗

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read ↗

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.Semantic proximity Read ↗

[Several hot issues in the detection of plasma EGFR mutations in advanced non-small-cell lung cancer patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.